Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...

These prices, reflecting discounts of 38% to 79% off list prices ... the efficacy and safety of once weekly, subcutaneous semaglutide 7.2 mg compared with Wegovy and placebo in adults with ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Semaglutide’s selection was based on a set ... The first round of Medicare negotiations yielded discounts on drugs ranging from 40 percent to 80 percent, including 76 percent off the list ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...